Labcorp Holdings Inc. $LH Shares Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D raised its stake in Labcorp Holdings Inc. (NYSE:LH) by 9.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,439 shares of the medical research company’s stock after buying an additional 2,491 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Labcorp were worth $8,164,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Caldwell Trust Co purchased a new position in Labcorp in the 2nd quarter valued at approximately $25,000. Financial Gravity Companies Inc. acquired a new stake in Labcorp in the second quarter valued at $26,000. Motco purchased a new position in shares of Labcorp in the third quarter valued at $32,000. Hantz Financial Services Inc. raised its stake in shares of Labcorp by 48.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock worth $35,000 after buying an additional 40 shares during the last quarter. Finally, Headlands Technologies LLC boosted its position in shares of Labcorp by 300.0% in the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock worth $34,000 after buying an additional 96 shares in the last quarter. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Q4 adjusted EPS beat estimates — LH reported $4.07 vs. consensus ~$3.95, showing ~18% EPS growth and improved profitability metrics. Labcorp Holdings (LH) Q4 Earnings Surpass Estimates
• Positive Sentiment: Company gave FY2026 guidance for adjusted EPS $17.55–$18.25 and revenue $14.61B–$14.79B, and projected higher free cash flow — guidance supports multi-year earnings growth assumptions. Labcorp Announces 2025 Fourth Quarter and Full Year Results
• Positive Sentiment: Management highlighted operational wins that can support long-term revenue expansion: 13 health-system/local lab partnerships, >130 new specialty tests launched in 2025, and a planned 500k sq ft central lab investment. Labcorp Announces 2025 Fourth Quarter and Full Year Results
• Neutral Sentiment: FY2026 guidance is broadly in line with consensus (midpoint roughly matches Street estimates), leaving limited surprise upside from guidance alone. Labcorp forecasts upbeat annual profit on strong demand for diagnostic products
• Negative Sentiment: Revenue missed expectations: Q4 revenue was $3.52B vs. consensus ~$3.56B (though up ~5.6% YoY), driving concern that top-line momentum is weaker than EPS suggests. Labcorp beats Q4 earnings estimates, revenue falls short
• Negative Sentiment: Market reaction: shares slipped on the revenue miss and cautious commentary, with pre-market/early trading weakness noted in several outlets. Labcorp Q4 Earnings Beat, Revenues Miss, Stock Down in Pre-Market
• Negative Sentiment: Insider activity: the CEO sold about $1.5M of stock recently — a potential near-term sentiment headwind for investors. Insider Selling: Labcorp (NYSE:LH) CEO Sells $1,499,535.74 in Stock

Analysts Set New Price Targets

LH has been the subject of several recent research reports. Robert W. Baird set a $313.00 target price on shares of Labcorp in a report on Wednesday, January 14th. JPMorgan Chase & Co. raised their price objective on shares of Labcorp from $317.00 to $319.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Weiss Ratings upgraded Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a report on Tuesday. Finally, UBS Group dropped their price target on Labcorp from $325.00 to $320.00 and set a “buy” rating for the company in a research report on Wednesday, October 29th. Ten equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Labcorp currently has an average rating of “Moderate Buy” and a consensus price target of $300.75.

Insider Activity at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 5,273 shares of Labcorp stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $284.38, for a total value of $1,499,535.74. Following the transaction, the chief executive officer owned 87,343 shares in the company, valued at $24,838,602.34. This trade represents a 5.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jonathan C. Meltzer sold 87 shares of the company’s stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $290.42, for a total value of $25,266.54. Following the sale, the executive vice president owned 2,782 shares of the company’s stock, valued at approximately $807,948.44. The trade was a 3.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.84% of the company’s stock.

Labcorp Price Performance

Shares of NYSE:LH opened at $276.53 on Wednesday. The company has a market cap of $22.92 billion, a P/E ratio of 27.16, a P/E/G ratio of 1.78 and a beta of 1.03. The business has a fifty day simple moving average of $264.43 and a 200-day simple moving average of $268.92. Labcorp Holdings Inc. has a 52 week low of $209.38 and a 52 week high of $293.72. The company has a quick ratio of 1.35, a current ratio of 1.55 and a debt-to-equity ratio of 0.59.

Labcorp (NYSE:LH) last released its earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, topping the consensus estimate of $3.95 by $0.12. The firm had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.56 billion. Labcorp had a return on equity of 15.85% and a net margin of 6.21%.The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.45 earnings per share. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Equities research analysts forecast that Labcorp Holdings Inc. will post 16.01 EPS for the current year.

Labcorp Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Investors of record on Friday, February 27th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Friday, February 27th. Labcorp’s payout ratio is presently 28.29%.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.